Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three-arm, randomized controlled Phase II trial

Journal of Clinical Oncology

Volumn 34, Issue 13, 2016, Pages 1500-1509

  Petrylak, Daniel P ^a   Tagawa, Scott T ^b   Kohli, Manish ^d   Eisen, Andrea ^e   Canil, Christina ^g   Sridhar, Srikala S ^f   Spira, Alexander ^h,i   Yu, Evan Y ^k   Burke, John M ^j,l   Shaffer, David ^c,j   Pan, Chong Xian ^m   Kim, Jenny J ^o   Aragon Ching, Jeanny B ^p   Quinn, David I ⁿ   Vogelzang, Nicholas J ^j,q   Tang, Shande ^r   Zhang, Hui ^r   Cavanaugh, Christopher T ^r   Gao, Ling ^r   Kauh, John S ^r   Walgren, Richard A ^s   Chi, Kim N ^h   more..

^a YALE CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c New York Oncology Hematology   (United States)

^d MAYO CLINIC   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ Virginia Cancer Specialists   (United States)

^j US Oncology Research   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^l ROCKY MOUNTAIN CANCER CENTERS   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^q Division of Hematology and Medical Oncology   (United States)

^r Eli Lilly and Company   (United States)

^s ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; HEMOGLOBIN; ICRUCUMAB; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; IMC-18F1; MONOCLONAL ANTIBODY; TAXOID;

ACCUMULATION INDEX; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIANGIOGENIC THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VISCERAL METASTASIS; VOLUME OF DISTRIBUTION; VOMITING; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; UROLOGIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS; UROLOGIC NEOPLASMS;

EID: 84968718780     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.0218     Document Type: Article

References (38)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Sternberg CN, Yagoda A, Scher H.I., et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the uro thelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
3. Loehrer PJ S.r., Einhorn LH, Elson P.J., et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
4. Saxman SB, Propert KJ, Einhorn L.H., et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
5. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus metho trexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
6. McCaffrey JA, Hilton S, Mazumdar M., et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
7. Choueiri TK, Ross RW, Jacobus S, et al: Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30:507-512, 2012
8. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71, 1992
9. Dickinson AJ, Fox SB, Persad R.A., et al: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74:762-766, 1994
10. Jaeger TM, Weidner N, Chew K., et al: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154:69-71, 1995
11. Sato K, Sasaki R, Ogura Y., et al: Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med 185:173-184, 1998
12. Crew JP, O'Brien T, Bicknell R, et al: Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161: 799-804, 1999
13. Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6:4866-4873, 2000
14. Xia G, Kumar SR, Hawes D, et al: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175:1245-1252, 2006
15. Mazzola CR, Chin J: Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin Investig Drugs 24:913-927, 2015
16. Necchi A, Mariani L, Zaffaroni N., et al: Pazopanib in advanced and platinum-resistant urothelial cancer: An open-label, single group, phase 2 trial. Lancet Oncol 13:810-816, 2012
17. Twardowski P, Stadler WM, Frankel P, et al: Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: A California Cancer Consortium Trial. Urology 76: 923-926, 2010
18. Balar AV, Apolo AB, Ostrovnaya I, et al: Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 31:724-730, 2013
19. Geldart T, Chester J, Casbard A., et al: SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. Eur Urol 67:599-602, 2015
20. Grivas PD, Daignault S, Tagawa S.T., et al: Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120:692-701, 2014
21. Krege S, Rexer H, vom Dorp F, et al: Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or meta-stasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int 113:429-436, 2014
22. Dreicer R, Li H, Stein M., et al: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: A trial of the Eastern Cooperative Oncology Group. Cancer 115:4090-4095, 2009
23. Spratlin JL, Cohen RB, Eadens M, et al: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780-787, 2010
24. Fuchs CS, Tomasek J, Yong C.J., et al; REGARD trial investigators: Ramucirumab mono therapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multi centre, placebo-controlled, phase 3 trial. Lancet 383: 31-39, 2014
25. Wilke H, Muro K, Van Cutsem E, et al; RAINBOW study group: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15:1224-1235, 2014
26. Tabernero J, Yoshino T, Cohn A.L., et al; RAISE study investigators: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499-508, 2015
27. Garon EB, Ciuleanu TE, Arrieta O, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV nonsmall-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665-673, 2014
28. Wu Y, Zhong Z, Huber J., et al: Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 12:6573-6584, 2006
29. LoRusso PM, Krishnamurthi S, Youssoufian H., et al: Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: A phase 1 study. Invest New Drugs 32:303-311, 2014
30. Smith TJ, Khatcheressian J, Lyman G.H., et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
31. Eisenhauer EA, Therasse P, Bogaerts J., et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
32. Petrylak DP, Tagawa ST, Kohli M, et al: Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. J Clin Oncol 33:7s, 2015 (suppl; abstr 295)
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
34. Yoshino T, Yamazaki K, Gotoh M., et al: Safety and pharmacokinetics of second-line ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma. Anticancer Res 35:4003-4007, 2015
35. Ueda S, Satoh T, Gotoh M., et al: A phase Ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist 20: 493-494, 2015
36. Bellmunt J, Théodore C, Demkov T., et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
37. Erratum: J Clin Oncol 28:182, 2010
38. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562, 2014